Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults
# Purpose of Review Migraines are prevalent and cause significant morbidity, decline in quality of life and healthcare costs universally. Treatment options are varied, but efficacy is limited. This review centers on Eptinezumab-jjmr, a humanized monoclonal specific to CGRP for the prevention of mig...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-11-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.38439 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139380541456384 |
|---|---|
| author | Amnon A. Berger Joseph Keefe Cain W. Stark Matthew Moore Giovanni F. Ramírez Julia R. Cucarola Andrew H. Han Alan D. Kaye Latha Ganti |
| author_facet | Amnon A. Berger Joseph Keefe Cain W. Stark Matthew Moore Giovanni F. Ramírez Julia R. Cucarola Andrew H. Han Alan D. Kaye Latha Ganti |
| author_sort | Amnon A. Berger |
| collection | DOAJ |
| description | # Purpose of Review
Migraines are prevalent and cause significant morbidity, decline in quality of life and healthcare costs universally. Treatment options are varied, but efficacy is limited. This review centers on Eptinezumab-jjmr, a humanized monoclonal specific to CGRP for the prevention of migraines in adults. Herein presented are the science and mechanism of action, indication and clinical evidence for use.
# Recent Findings
Migraines are severe, recurrent headaches, which are either episodic or chronic in nature. The pain is severe, often accompanied by co-morbid symptoms, such as photophobia, phonophobia, nausea and emesis, and is limiting in nature. It is a prevalent disorder that causes significant, worldwide disability, morbidity, suffering, and costs.
The pathophysiology of migraines is actively studied, though recent research points to an initiating event causing migraine generation, that is then propagated by other brain regions, a significant one being the trigeminocervical complex. This is driven by biochemical transmitters, chiefly CGRP. This discovery led to the development of CGRP-targeting drugs, including gepants (small molecular antagonists) and anti-CGRP antibodies, such as Eptinezumab-jjmr.
Traditional therapy includes preventative and abortive treatment; however, adherence with preventative treatment has been historically poor, and certain types of abortive therapy carry risks and side effects that preclude them from a large patient population. Moreover, traditional therapy often falls short in migraine therapy. CGRP antagonist, including Eptinezumab, aims to cover the gaps in migraine therapy. We present here evidence to support the safe and effective use of Eptinezumab for the prevention of migraines.
# Summary
Migraines are a prevalent primary headache disorder causing significant morbidity worldwide. Traditional abortive and preventative treatments fall short for many patients. Eptinezumab is part of new generation of CGRP-targeting medications and has shown significant evidence to support its use for the prevention of migraines. Further research is required to properly compare eptinezumab with existing pharmacotherapy and update guidelines on the appropriate combinations of therapies that are not available and the correct patient selection for each. |
| format | Article |
| id | doaj-art-2d7dcfee40df4768a84803a29a86e5cd |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-2d7dcfee40df4768a84803a29a86e5cd2025-02-11T20:30:32ZengOpen Medical PublishingHealth Psychology Research2420-81242022-11-01105Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adultsAmnon A. BergerJoseph KeefeCain W. StarkMatthew MooreGiovanni F. RamírezJulia R. CucarolaAndrew H. HanAlan D. KayeLatha Ganti# Purpose of Review Migraines are prevalent and cause significant morbidity, decline in quality of life and healthcare costs universally. Treatment options are varied, but efficacy is limited. This review centers on Eptinezumab-jjmr, a humanized monoclonal specific to CGRP for the prevention of migraines in adults. Herein presented are the science and mechanism of action, indication and clinical evidence for use. # Recent Findings Migraines are severe, recurrent headaches, which are either episodic or chronic in nature. The pain is severe, often accompanied by co-morbid symptoms, such as photophobia, phonophobia, nausea and emesis, and is limiting in nature. It is a prevalent disorder that causes significant, worldwide disability, morbidity, suffering, and costs. The pathophysiology of migraines is actively studied, though recent research points to an initiating event causing migraine generation, that is then propagated by other brain regions, a significant one being the trigeminocervical complex. This is driven by biochemical transmitters, chiefly CGRP. This discovery led to the development of CGRP-targeting drugs, including gepants (small molecular antagonists) and anti-CGRP antibodies, such as Eptinezumab-jjmr. Traditional therapy includes preventative and abortive treatment; however, adherence with preventative treatment has been historically poor, and certain types of abortive therapy carry risks and side effects that preclude them from a large patient population. Moreover, traditional therapy often falls short in migraine therapy. CGRP antagonist, including Eptinezumab, aims to cover the gaps in migraine therapy. We present here evidence to support the safe and effective use of Eptinezumab for the prevention of migraines. # Summary Migraines are a prevalent primary headache disorder causing significant morbidity worldwide. Traditional abortive and preventative treatments fall short for many patients. Eptinezumab is part of new generation of CGRP-targeting medications and has shown significant evidence to support its use for the prevention of migraines. Further research is required to properly compare eptinezumab with existing pharmacotherapy and update guidelines on the appropriate combinations of therapies that are not available and the correct patient selection for each.https://doi.org/10.52965/001c.38439 |
| spellingShingle | Amnon A. Berger Joseph Keefe Cain W. Stark Matthew Moore Giovanni F. Ramírez Julia R. Cucarola Andrew H. Han Alan D. Kaye Latha Ganti Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults Health Psychology Research |
| title | Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults |
| title_full | Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults |
| title_fullStr | Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults |
| title_full_unstemmed | Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults |
| title_short | Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults |
| title_sort | eptinezumab jjmr a humanized monoclonal specific to calcitonin gene related peptide for the preventive treatment of migraine in adults |
| url | https://doi.org/10.52965/001c.38439 |
| work_keys_str_mv | AT amnonaberger eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT josephkeefe eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT cainwstark eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT matthewmoore eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT giovanniframirez eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT juliarcucarola eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT andrewhhan eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT alandkaye eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults AT lathaganti eptinezumabjjmrahumanizedmonoclonalspecifictocalcitoningenerelatedpeptideforthepreventivetreatmentofmigraineinadults |